The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo
Open accessAbstract
Background: Osteosarcoma (OS) mainly happens in children and youths. Surgery, radiotherapy and chemotherapy are the common therapies for osteosarcoma treatment but all their anti-tumor effects are limited. In recent years, a new cellular therapy, CAR-T, a cellular immunotherapy with genetically engineered T cells bearing chimeric antigen receptor targeting specific tumor-associated antigen, has been proved to be an effective therapy against acute lymphoblastic leukemia. Thus, CAR-T is a potentially effective therapy for osteosarcoma treatment. Methods: A CAR gene targeting B7-H3 antigen was constructed into lentiviral vector through molecular biology techniques. Then, the CAR gene was transferred to T cells through lentiviral delivery system, and the CAR-T cells were largely expanded using in vitro culture technology. The in vitro anti-tumor effect of CAR-T cells was evaluated through Real Time Cell Analysis system (RTCA) and ELISA assay. The in vivo anti-tumor capabilities of CAR-T cells were evaluated using the patient-derived xenografts (PDX) model of osteosarcoma. Results: The third-generation CAR-T cells we constructed could target the B7-H3 antigen, and the phenotype of CAR-T cells was consistent with normal T cells; The CAR-T cells showed superior antitumor effects both in vitro and in vivo. Conclusion: Our study showed that B7-H3 targeted CAR-T cells had high anti-tumor efficacy against osteosarcoma both in vitro and in vivo, which proved that B7-H3 targeted CAR-T therapy is potentially effective for osteosarcoma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Zhang et al. conducted the third-generation CAR-T cells targeting B7-H3 and proved the killing effects for tumor cells in vitro and in vivo using the patientderived xenografts (PDXs) model of osteosarcoma [116–125].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860 · cited 1×
“CAR-T cell immunotherapy has shown excellent efficacy in the treatment of hematologic tumors [6].”
BackgroundCAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851 · cited 1×
“The solid tumors have more hidden presence or more complicated tumor microenvironments compared to the hematologic malignancies, which may limit the use of CAR-T cell therapy for treating solid tumor [31, 32].”
BackgroundAdachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792 · cited 1×
“Some studies showed that addition of cytokines and chemokines could enhance the anti-tumor effect of CAR-T cells in mice [33, 34].”
BackgroundMajzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639 · cited 1×
“The solid tumors have more hidden presence or more complicated tumor microenvironments compared to the hematologic malignancies, which may limit the use of CAR-T cell therapy for treating solid tumor [31, 32].”
BackgroundMolecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582 · cited 1×
“It is reported that the expression level of B7-H3 is closely related to tumor metastasis, tumor immune escape, prognosis, and clinical outcome [22, 23].”
BackgroundDu, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D., Greene, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.002 · Cited by 479 · cited 2×
“Since we did not obtain the paracancerous tissue of osteosarcoma, we clearly observed that B7-H3 protein was highly expressed in osteosarcoma by referring to the expression level of B7-H3 in normal tumor tissue in other articles [24, 29].”
BackgroundSeaman, S., Zhu, Z., Saha, S., Zhang, X. M., Yang, M. Y., Hilton, M. B., Morris, K., Szot, C., Morris, H., Swing, D. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.005 · Cited by 423
Moore, D. D., & Luu, H. H. (2014) · Cancer Treatment and Research · doi:10.1007/978-3-319-07323-1_4 · Cited by 349
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Zhang et al. conducted the third-generation CAR-T cells targeting B7-H3 and proved the killing effects for tumor cells in vitro and in vivo using the patientderived xenografts (PDXs) model of osteosarcoma [116–125].”
Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis
Nirala, B. K., Yamamichi, T., Petrescu, D. I., Shafin, T. N., & Yustein, J. T. (2023) · Cancers · doi:10.3390/cancers15205108 · Cited by 57
“B7-H3 targeted CAR-T cells had high antitumor efficacy against OS in vitro and in vivo [191].”
BackgroundNiu, Z., Wu, J., Zhao, Q., Zhang, J., Zhang, P., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1385571 · Cited by 56
Li, X., Zhao, L., Li, W., Gao, P., & Zhang, N. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00275-6 · Cited by 46
“Situations where the experiment needed to be paused immediately were listed as previously reported [21].”
MethodLuo, T., Fan, Z., Zeng, A., Wang, A., Pan, Y., Xu, Y., Chen, H., Chen, W., Nie, D., Lin, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202410427 · Cited by 44
Self-citation
Metadata
- Authors
- Zhang, Q., Zhang, Z., Liu, G., Li, D., Gu, Z., Zhang, L., Pan, Y., Cui, X., Wang, L., Liu, G., Tian, X., & Zhang, Z.
- Affiliations
- Shanghai Jiao Tong University (CN)
- East China University of Science and Technology (CN)
- Corresponding author
- Zhang, Zhiqiang
- Li, Dehua
- Liu, Guoping
- Tian, Xiaoli
- Zhang, Ziming
- Venue
- BMC Cancer
- Published
- 2022-11-02
- Volume
- 22
- Issue
- 1
- Pages
- 1124-1124
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC9628043
- OpenAlex
- W4308139559
- Cited by
- 51
- References
- 36
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 17 · 2023: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Shanghai Science and Technology Committee (19ZR1454700)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- osteosarcoma, B7-H3, chimeric antigen receptor T cells, chimeric antigen receptor, lentiviral vectors, third-generation CAR, patient-derived xenografts, antitumor efficacy, T cell engineering
- MeSH terms
- Receptors, Chimeric Antigen, Bone Neoplasms, Humans, Osteosarcoma, T-Lymphocytes, Immunotherapy, Adoptive, Xenograft Model Antitumor Assays, Cell Line, Tumor, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. https://app.cochat.ai/papers/10.1186/s12885-022-10229-8
- The paper
- Zhang, Q., Zhang, Z., Liu, G., Li, D., Gu, Z., Zhang, L., Pan, Y., Cui, X., Wang, L., Liu, G., Tian, X., & Zhang, Z. (2022). B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer. https://doi.org/10.1186/s12885-022-10229-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.